Clinical Trial

Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 15, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study aims to assess whether transmusculr quadratus lomborum block (QL block) can reduce postoperative pain after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS and HIPEC). Patients will be randomly assigned to either QL block group or control group. Ultrasound-guided bilateral transmuscular quadratus lomborum block will be performed in QL block group using 0.375% ropivacaine. Multimodal analgesic regimen including acetaminophen, nonsteroidal antiinflammatory drugs (NSAIDs), and rescue opioids will be used in every patient. Primary outcome is opioid consumption for 24 hours after surgery. Secondary outcomes included pain scores, time to first rescue analgesics, quality of recovery score, length of hospital stay.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-10-25; most recent amendment 2024-08-14.
Status change: Not Yet Recruiting → Recruiting 2022-12-02
Trial Details
NCT Number NCT05597683
Lead Sponsor Gangnam Severance Hospital
Conditions Cytoreductive Surgery, Hyperthermic Intra-peritoneal Chemotherapy, Peritoneal Cancer
Enrollment 50 participants
Start Date 2022-11-15
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-01-10 (estimated)
Updated on ClinicalTrials.gov 2024-08-15